Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Giovanni Guaraldi; Marianna Meschiari; Alessandro Cozzi‐Lepri; Jovana Milić; Roberto Tonelli; Marianna Menozzi; Erica Franceschini; Gianluca Cuomo; Gabriella Orlando; Vanni Borghi; Antonella Santoro; Margherita Di Gaetano; Cinzia Puzzolante; Federica Carli; Andrea Bedini; Luca Corradi; Riccardo Fantini; Ivana Castaniere; Luca Tabbì; Massimo Girardis; Sara Tedeschi; Maddalena Giannella; Michele Bartoletti; Renato Pascale; Giovanni Dolci; Lucio Brugioni; Antonello Pietrangelo; Andrea Cossarizza; Federico Pea; Enrico Clini; Carlo Salvarani; Marco Massari; P. Viale; Cristina Mussini

doi:10.1016/s2665-9913(20)30173-9

Keywords

TocilizumabCoronavirus disease 2019 (COVID-19)MedicineRetrospective cohort studySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCohortVirologyInternal medicineOutbreakRheumatoid arthritisDisease

Affiliated Institutions

Related Publications

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study

Shufa Zheng , Jian‐Gao Fan , Fei Yu +28 more

Abstract Objective To evaluate viral loads at different stages of disease progression in patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Co...

2020 BMJ 1567 citations

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Li Tan , Qi Wang , Duanyang Zhang +5 more

Background: Coronavirus disease-2019 (COVID-19) is a rapidly escalating epidemic caused by SARS-CoV-2. Identification of a simple and effective indicator to assess disease sever...

2020 Signal Transduction and Targeted Therapy 1583 citations

Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission

Jennifer Lighter , Michael Phillips , Sarah Hochman +4 more

Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital AdmissionTo the Editor-Risk factors for infectious disease severity are determined by the pathog...

2020 Clinical Infectious Diseases 1279 citations

Clinical and immunological features of severe and moderate coronavirus disease 2019

Guang Chen , Di Wu , Wei Guo +17 more

BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is...

2020 Journal of Clinical Investigation 4983 citations

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Evangelos J. Giamarellos‐Bourboulis , Mihai G. Netea , Νikoletta Ρovina +25 more

Proper management of COVID-19 mandates better understanding of disease pathogenesis. The sudden clinical deterioration 7-8 days after initial symptom onset suggests that se...

2020 Cell Host & Microbe 2195 citations

Publication Info

Year: 2020
Type: article
Volume: 2
Issue: 8
Pages: e474-e484
Citations: 988
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

988

OpenAlex

Cite This

APA Style

                            
                                
                                    Giovanni Guaraldi, 
                                
                                    Marianna Meschiari, 
                                
                                    Alessandro Cozzi‐Lepri
                                
                                et al.
                            
                            (2020). 
                            Tocilizumab in patients with severe COVID-19: a retrospective cohort study. 
                            The Lancet Rheumatology
                            , 2
                            (8)
                            , e474-e484.
                            https://doi.org/10.1016/s2665-9913(20)30173-9
                        

Identifiers

DOI: 10.1016/s2665-9913(20)30173-9